XP Q2 Earnings Preview: Consensus Estimates, Revisions, and Outlook

XP is set to announce Q2 2025 earnings on Aug 18th, after market close. The consensus EPS estimate is $0.42, with revenue expected at $813.46M. Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward, while revenue estimates have seen 0 upward revisions and 3 downward.

XP Inc. (XP) is set to release its Q2 2025 earnings on August 18th, after market close. Analysts anticipate an earnings per share (EPS) of $0.42, with revenue expected at $813.46 million. Over the past three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates have seen three downward revisions.

XP Inc. is a Cayman Island-based technology-driven financial services platform that provides low-fee financial products and services in Brazil. The company evaluates its business through a single segment, focusing on monitoring operations, fund allocation decisions, and performance evaluation. It generates revenue primarily through brokerage commissions.

The company has shown positive performance in recent quarters. For instance, during the last quarter, XP reported an EPS beat by $0.01, leading to a 0.48% increase in the share price on the subsequent day. This trend indicates investor confidence in the company's strategic direction and its ability to meet expectations.

XP's stock has been volatile, with shares trading at $17.39 as of August 14, down 11.75% over the last 52-week period. Analysts have given XP a total of four ratings, with the consensus rating being a "Buy." The average one-year price target is $20.75, indicating a potential 19.32% upside.

Key Takeaways:
- EPS Estimate: $0.42 per share
- Revenue Estimate: $813.46 million
- EPS Revisions: 2 upward, 1 downward over the past three months
- Revenue Revisions: 0 upward, 3 downward over the past three months
- Stock Performance: Down 11.75% over the last 52 weeks, trading at $17.39
- Analyst Sentiment: 4 ratings, consensus rating is "Buy," with an average one-year price target of $20.75

Investors are eagerly awaiting the earnings announcement, hoping for favorable guidance and a potential beat on estimates. The company's ability to navigate market volatility and maintain strong performance will be key factors in determining its stock price movement post-announcement.

References:
[1] https://www.benzinga.com/insights/earnings/25/08/47155563/xps-earnings-a-preview
[2] https://www.investing.com/news/transcripts/earnings-call-transcript-allogene-therapeutics-q2-2025-earnings-reveal-strategic-shifts-93CH-4190387